Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of MeiraGTx's AAV-AQP1?
AAV-AQP1 is a gene therapy commercialized by MeiraGTx, with a leading Phase II program in Sicca Syndrome (Sjogren). According to...
AAV-AQP1 by MeiraGTx for Sicca Syndrome (Sjogren): Likelihood of Approval
AAV-AQP1 is under clinical development by MeiraGTx and currently in Phase II for Sicca Syndrome (Sjogren). According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of MeiraGTx's AAV-AQP1?
AAV-AQP1 is a gene therapy commercialized by MeiraGTx, with a leading Phase II program in Xerostomia. According to Globaldata, it...